U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...

Novo Nordisk's CEO faced lawmakers in a grueling 2.5-hour hearing to discuss the cost of blockbuster drugs Ozempic and Wegovy ...

Lawmakers say the drug company has made $50 billion on the sales of those two drugs since 2018. Tuesday, members of the U.S.

CEO Lars Fruergaard Jørgensen told lawmakers the company would consider new talks with insurers about the list prices of Wegovy and Ozempic if they pledge to keep the medicines on their formularies.

"All we are saying [to Novo Nordisk] is, Treat the American people the same way that you treat people all over the world.

Here are five key takeaways: During the hearing, Novo Nordisk CEO Lars Fruergaard Jørgensen attributed the high prices of drugs such as Ozempic and Wegovy to PBMs, arguing that "a high list price is ...

The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...

While grilling Novo Nordisk’s chief executive over the price of its blockbuster diabetes and weight-loss drugs, Ozempic and ...

A key goal of President Biden’s Inflation Reduction Act was to lower drug prices for seniors. That would have been readily achievable — by curtailing the practices of the supply chain middlemen ...

No, if Novo Nordisk lowered their list price for Ozempic and Wegovy tomorrow to a price that was the same or lower than current net cost, that change by itself would not result in less favorable ...

When government officials and politicians scrutinize high U.S. drug prices, the role of insurers and pharmacy benefit ...